49th week of 2011 patent applcation highlights part 36 |
Patent application number | Title | Published |
20110300079 | COMPOSITIONS FOR USE WITH A SYSTEM FOR IMPROVED COOLING OF SUBCUTANEOUS LIPID-RICH TISSUE - A composition or cryoprotectant for use with a system for improved cooling of subcutaneous lipid-rich tissue of a subject having skin is provided. The cryoprotectant is a non-freezing liquid, gel, or paste for allowing pre-cooling of a treatment device below about 0° C. while preventing the formation of ice thereon. The cryoprotectant may also prevent freezing of the treatment device to the skin and protect tissue of a subject from freezing damage due to, e.g., ice formation. The cryoprotectant can also include an authentication or anti-counterfeiting agent to authenticate an origin of the cryoprotectant, a lubricating agent to increase lubriciousness of the cryoprotectant, and a thixotropic or pseudoplastic agent in an amount effective substantially to render the gel dimensionally stable unless agitated. | 2011-12-08 |
20110300080 | ACIDIFIED CHLORITE DISINFECTANT COMPOSITIONS WITH OLEFIN STABILIZERS - A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part comprises an acid, and wherein the first part, the second part, or both the first and second parts comprise an olefin compound. | 2011-12-08 |
20110300081 | OROSOLUBLE AND/OR EFFERVESCENT COMPOSITIONS CONTAINING AT LEAST A SALT OF S-ADENOSYL METHIONINE (SAME) - The present invention refers to pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent compositions for oral use containing at least a salt of S-adenosyl methionine (SAMe), combined with physiologically acceptable excipients and optionally additional active ingredients. In particular the invention refers to compositions with high palatability formulated in tablet, capsule or granules. The present invention also refers to the use of at least a salt of SAMe combined with physiologically acceptable excipients and optionally further active ingredients for treating, human or veterinarian, neuropsychiatric, osteoarticular or hepatic diseases. | 2011-12-08 |
20110300082 | PARTIAL ESTERS OF A POLYGLYCEROL WITH AT LEAST ONE CARBOXYLIC ACID AND ONE POLYFUNCTIONAL CARBOXYLIC ACID, THEIR PREPARATION AND USE - The present disclosure relates to specific (poly-)glycerol partial esters with at least one carboxylic acid and one polyfunctional carboxylic acid, and to the use thereof as emulsifier and to formulations comprising partial esters of the present disclosure. | 2011-12-08 |
20110300083 | PERSONAL CARE FORMULATIONS CONTAINING ALKYL KETAL ESTERS AND METHODS OF MANUFACTURE - Personal care formulations containing alkyl ketal esters having the structure | 2011-12-08 |
20110300084 | DETOXIFICATION METHOD FOR OBTAINING A ZINC CONTAINING PIGMENT COMPOUND WITH NO ECOTOXICITY - A detoxification method for obtaining a pigment compound free from acute and chronic aquatic ecotoxicity by mixing at least one zinc-based component with good anti-corrosive properties but high toxicity-with a phosphate or hydrogen phosphate of a magnesium, sodium, potassium, calcium, strontium, aluminum, ammonium, or organic type or any other compound based on such cations, such as carbonates, oxides, silicates, phosphites, pyrophosphates or phosphonates, said phosphates or hydrogen carbonates or carbonates or oxides or silicates or phosphites or pyrophosphates freed from toxicity enabling a very considerable reduction of the toxic power of said zinc-based component, while maintaining the good anti-corrosive properties thereof. | 2011-12-08 |
20110300085 | Home And Personal Care Compositions - The present invention relates to home and personal care compositions comprising a silicone oil-in-water emulsion stabilized by a protein or peptide and at least one home and/or personal care ingredient. Such compositions tend to provide desirable characteristics for the care and conditioning of hair, skin and fabric. | 2011-12-08 |
20110300086 | Film-Forming Solutions Comprising Vitamin D or Derivative Thereof and a Corticosteroid and Dermatological Applications Thereof - Topically applicable film-forming solutions, e.g., nail varnishes, useful for such dermatological applications as the prevention or treatment of nail psoriasis, contain, as active agents solubilized therein, vitamin D or derivative thereof and a corticosteroid, formulated into a topically applicable, physiologically acceptable medium therefor. | 2011-12-08 |
20110300087 | TRANSFER-RESISTANT AND LONG WEAR FOUNDATION IN EMULSION FORM CONTAINING OIL ABSORBING POWDERS - The present invention is directed to a transfer resistant and long wear cosmetic composition having a unique gel-like texture with good pickup, payoff, and spreadability properties, as well as a silky smooth feel containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) at least one volatile solvent; (e) at least one non-volatile solvent; (f) at least one water soluble surfactant; (f) at least one colorant; and (g) at least one oil absorbing powder. | 2011-12-08 |
20110300088 | WATER-INSOLUBLE REACTION PRODUCT OF A POLYAMINE AND AN OIL-SOLUBLE POLAR MODIFIED POLYMER - The invention relates to a water-insoluble reaction product of an oil-soluble polar modified polymer and a polyamine. | 2011-12-08 |
20110300089 | HYDRATING AND MOISTURIZING AQUEOUS LIP GLOSS COMPOSITION - The present invention is directed to an aqueous lip gloss composition imparting high gloss, non-sticky, hydration and moisturization onto lips having: (a) at least one alkyl ethoxylated polymer wax; (b) at least one oil soluble high carbon polar modified polymer; (c) water; (d) at least one non-volatile oil capable of solubilizing the polar modified polymer; and (e) optionally, at least one colorant, and wherein the composition does not require silicone fluids to impart gloss. | 2011-12-08 |
20110300090 | NON-STICKY, HYDRATING AND MOISTURIZING AQUEOUS LIP GLOSS COMPOSITION - The present invention is directed to a non-sticky, hydrating and moisturizing aqueous lip gloss having: (a) at least one alkyl ethoxylated polymer wax; (b) at least one oil soluble polar modified polymer; (c) water; (d) at least one non volatile oil capable of solubilizing the polar modified polymer; and (e) optionally, at least one colorant, and wherein the composition does not require silicone fluids therein. | 2011-12-08 |
20110300091 | TRANSLUCENT DEODORANT STICKS CONTAINING SOLUBILIZED 3,4,4'-TRICHLOROCARBANILIDE - The present invention is a solid translucent deodorant stick that exhibits remarkable efficacy against gram positive bacteria. Maintenance of translucency in spite of a high level of antimicrobial is possible through use of solubilized 3,4,4′-trichlorocarbanilide. The solubilized TCC is formed as a premix which is then added to the some or all of the remaining ingredients comprising a stearate-gelled glycol solvent stick. | 2011-12-08 |
20110300092 | MASCARAS OBTAINED VIA MULTI-PHASE PRODUCT - Disclosed is a multi-phase mascara product, including a first container having disposed therein a first phase comprising a wax, a second container having disposed therein a second phase comprising a film forming polymer, and a third container into which relative amounts of said first and second phases may be introduced, wherein upon mixing of the first and second phases, the third container comprises the wax, the film-forming polymer, a solvent and a thickener, wherein if the solvent and thickener are oil-soluble, they are present in the first phase, and if the solvent is aqueous and the thickener is water-soluble, they are present in the second phase. Also disclosed are methods of producing the mascara, by mixing relative amounts of the phases into a separate container. Further disclosed are methods of making up the eye lashes by application of the mascara. | 2011-12-08 |
20110300093 | COSMETIC COMPOSITION CONTAINING AN AMPHIPHILIC ZWITTERIONIC COPOLYMER - The present invention relates to a cosmetic composition that includes an amphiphilic zwitterionic copolymer. The amphiphilic zwitterionic copolymer can particularly be used for imparting rheological properties, in particular a beneficial texture, to said composition and/or to the foam resulting from said composition. | 2011-12-08 |
20110300094 | Silicone Oil-In-Water Emulsions - A silicone oil-in-water emulsion comprising 3 to 90% by volume of a silicone oil phase, characterized in that the emulsion is stabilized by a protein and/or peptide present at 0.25 to 20% by weight of the emulsion. The emulsion contains less than 25% by weight and preferably zero % by weight of non-polymeric amphiphilic surfactant based on the weight of protein or peptide. A process for preparing the emulsion is also described. | 2011-12-08 |
20110300095 | MALODOR NEUTRALIZING COMPOSITIONS COMPRISING UNDECYLENIC ACID OR CITRIC ACID - Compositions comprising undecylenic acid or citric acid and certain esters are effective for reducing malodors. The esters are in the molecular weight range of between 150-200 when the acid is undecylenic acid and in the range of between 130-230 when the acid is citric acid. These compositions can be used in perfumed products, household products and personal care products. | 2011-12-08 |
20110300096 | Polymers With Structure-Defined Functions - An alternating copolymer comprising a backbone of residues of a maleic anhydride derivative and those of a compound containing vinylic unsaturation, which also comprises residues of an active compound containing a nucleophilic group, bound to the backbone by a residue of the nucleophilic group, including such a copolymer comprising residues of an active compound containing an alcohol, thiol or amine group. The chemical and biological properties of actives, such as protease inhibitors, neurotransmitter drugs, and other small molecule active drugs, are enhanced, and new applications enabled. Also, artefacts, including a solid medical implant device, dressing or scaffold or a fluid adhesive or medicinal composition comprising such a polymer, and a method of use of such a polymer, including a method for the treatment or prophylaxis of wounds. | 2011-12-08 |
20110300097 | Method And Composition For The Treatment Of Moderate To Severe Keratoconjunctivitis Sicca - The present invention relates to topical ophthalmic compositions for treating or preventing epithelial lesions or ophthalmic disorders, including dry eye or keratoconjunctivitis sicca. | 2011-12-08 |
20110300098 | METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY - Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies. | 2011-12-08 |
20110300099 | MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS - A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described. | 2011-12-08 |
20110300100 | IL-11 MUTEINS - The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions. | 2011-12-08 |
20110300101 | Methods for treating viral infection using IL-28 and IL-29 Cysteine mutants - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 2011-12-08 |
20110300102 | COMPOSITION FOR SKIN REGENERATION, CONTAINING A SECRETION IN THE CULTURE OF AN EMBRYONIC STEM CELL-DERIVED ENDOTHELIAL PROGENITOR CELL OR FRACTIONS THEREOF, AND USE THEREOF - The present invention relates to a composition for skin regeneration, using a culture medium or a secretion in the culture of an embryonic stem cell-derived endothelial progenitor cell, and to the use thereof. As the present invention uses the secretion in the culture as a medicine and not the embryonic stem cell-derived endothelial progenitor cell itself, the risk of teratoma formation is prevented, and angiogenic activity is promoted to achieve improved effectiveness in healing wounds and burn wounds. The composition of the present invention, when used as a material in cosmetics, increases collagen synthesis and thus prevents skin aging. Particularly, the composition of the present invention in which the secretion in the culture is concentrated into a high concentration provides superior wound-healing effects as compared to a conventional human growth hormone (hGH). | 2011-12-08 |
20110300103 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R | 2011-12-08 |
20110300104 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-12-08 |
20110300105 | Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo - The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. In alternative embodiments, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases. | 2011-12-08 |
20110300106 | THERAPEUTIC AMOEBA AND USES THEREOF - The present invention relates to amoebae (slime molds) and uses thereof. In particular, the present invention relates to the use of amoebae or their environmentally stable spores to treat microbial infections and other uses. | 2011-12-08 |
20110300107 | Compositions and Methods to Treat Cardiac Pacing Conditions - The method may include administering to a subject in need thereof an effective amount of an HCN polynucleotide. The HCN polynucleotide includes a nucleotide sequence encoding an HCN polypeptide having channel activity. The amino acid sequence of the HCN polypeptide and the amino acid sequence of a reference polypeptide have at least 80% identity, where the reference polypeptide begins with an amino acid selected from amino acids 92-214 and ends with an amino acid selected from amino acids 723-1188 of SEQ ID NO:8. An example of a reference polypeptide is amino acids 214-723 of SEQ ID NO:8. The HCN polynucleotide may be DNA or RNA. | 2011-12-08 |
20110300108 | Herbal Compositions for the Control of Hematophagous Parasites - There is described an herbal hematophagous parasite control composition which comprises | 2011-12-08 |
20110300109 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention is based, in part, on our discovery of compositions and methods that can be used to systemically deplete arginine and thereby treat arginine-dependent cancers. Our studies indicate that administering a composition that depletes arginine directly to the patient's small intestine will provide effective treatment for arginine-dependent cancers. Moreover, the methods can be carried out in such a way that various sources of arginine are restricted and side effects are minimized. For example, to deplete arginine, one can not only administer an arginine-depleting enzyme directly to the intestinal lumen but can also inhibit endogenous production of arginine, reduce arginine production by intestinal bacteria and limit arginine intake. To minimize side effects, one can inhibit protein breakdown, which may occur as a compensatory mechanism, provide systemic NO from a nitric oxide donor, provide a pressor peptide, and/or provide prostacycline or an analog thereof. | 2011-12-08 |
20110300110 | ENAMINOCARBONYL COMPOUND/BENEFICIAL ORGANISM COMBINATIONS - The novel combinations of enaminocarbonyl compounds and beneficial species comprising, firstly, at least one enaminocarbonyl compound of the formula (I) | 2011-12-08 |
20110300111 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS WITHOUT THE USE OF VIRAL VECTORS - Presented herein, generally, are methods for generating reprogrammed mammalian cells, e.g., induced pluripotent stem cells, from differentiated mammalian cells without the use of viral or plasmid vectors. In one aspect, the methods involve contacting a differentiated cell with transducible polypeptides comprising a reprogramming factor polypeptide linked to a cell penetration peptide so that a reprogrammed mammalian cell that exhibits at least one characteristic of pluripotency is generated. Also presented herein are methods for cardiac differentiation of a mammalian cell without the use of viral or plasmid vectors. In one aspect, such methods involve contacting a mammalian cell exhibiting at least one characteristic of pluripotency with a transducible polypeptide, so that cardiac differentiation of the cell occurs. | 2011-12-08 |
20110300112 | METHODS FOR ENHANCING YIELD OF STEM CELL CULTURES AND ENHANCING STEM CELL THERAPY - The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies. | 2011-12-08 |
20110300113 | Death Receptor CD95 Controls Neurogenesis of Adult Neural Stem Cells in Vivo and in Vitro - The present invention relates to the activation of the CD95L/CD95 system for inducing neuronal differentiation in vitro and in vivo and the use of CD95L compositions to effect differentiation. | 2011-12-08 |
20110300114 | METHOD OF CELL CULTURE AND METHOD OF TREATMENT COMPRISING A vEPO PROTEIN VARIANT - In one aspect the present invention is concerned with a method of cell culture, comprising the steps of (i) obtaining a stem or progenitor cell sample, (ii) culturing the stem or progenitor cell sample in media and under closed conditions appropriate to cause proliferation or differentiation of the stem or progenitor cells, wherein the media comprises a vEPO protein variant, (iii) purifying the stem or progenitor cells ex vivo. The invention relates to a method of increasing the number and survival of stem and progenitor cells in vitro and in vivo using a vEPO protein variant. The invention also relates to improved differentiation of stem and progenitor cells in vitro and in vivo using a vEPO protein variant. | 2011-12-08 |
20110300115 | USE OF INDUCTOR AGENTS GSE24.2 FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR TREATING ILLNESSES RELATING TO CELLULAR SENESCENCE - This invention describes the use of an inductor or activator compound GSE24.2 for producing a medicament or pharmaceutical composition for treating a preferably human illness or pathological situation caused by a senescence process. Said pharmaceutical composition can be useful for a treatment of tissue regeneration, for example of epithelial tissues or haematopoietic cells, and also for the immortalisation of eukaryote cells for use of same in biotechnological research or processes. | 2011-12-08 |
20110300116 | Method for Generating a Recombinant Clonal Cell Line and Novel Reagents for Use in the Method - A method for generating a recombinant clonal cell line expressing a target cell surface receptor at a specific level of expression from a cell population comprising cells transfected with a plasmid encoding the cDNA sequence of the target receptor and expressing the target cell surface receptor, the method comprising (c) incubating the cell population with a receptor specific fluorescent ligand (d) selecting single cells from step (c) expressing the target cell surface receptor by monitoring the specific binding of the fluorescent ligand using flow cytometry; and novel fluorescent ligands. | 2011-12-08 |
20110300117 | Novel Lactobacillus Strain, Composition and Use Thereof for Improving the Syndrome of Diabetes and Complication Thereof - The invention relates to a composition for improving the syndrome of diabetes and complication thereof. The composition comprises an effective amount of | 2011-12-08 |
20110300118 | AGENTS FOR PROMOTING IGA PRODUCTION - The present invention provides | 2011-12-08 |
20110300119 | METHODS OF ENRICHING AND USING REGULATORY T CELLS - Disclosed are methods of isolating and using a population of FOXP3 | 2011-12-08 |
20110300120 | OLIGOSACCHARIDE-PROTEIN CONJUGATES - Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate. | 2011-12-08 |
20110300121 | Stabilization Of Perhydrolases - Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided. | 2011-12-08 |
20110300122 | METHOD FOR TREATING A PATIENT - Intra-arterial administering at least one blood coagulation to a bleeding patient is provided, together with a pharmaceutical composition therefor. | 2011-12-08 |
20110300123 | PHARMACOLOGICAL VITREOLYSIS - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 2011-12-08 |
20110300124 | SOAKING AGENT FOR THE TREATMENT OF HEMORRHOIDS AND METHOD OF USE - A natural gel/ointment for the treatment of hemorrhoids. Bromelain is one primary active ingredient in the gel/ointment. A second active ingredient in the form of Witch Hazel may be combined with the Bromelain. Supplemental ingredients include alcohol, de-ionized water, Butylene Glycol, PEG-40 Hydrogenated Castor Oil, Hydroxyethylcellulose, | 2011-12-08 |
20110300125 | COMPOSITIONS AND METHODS FOR COMBINED THERAPY OF DISEASE - A desired physiological state can be induced by altering the amount of gene products in target cells of a subject. The target cells are treated with at least one compound designed to reduce expression of at least one first gene by RNAi, and with at least one compound designed to increase expression from at least one second gene. The reduced expression of the first gene and the increased expression from the second gene in the target cells induces the desired physiological state in the subject. By altering target cell gene expression in this way, conditions such as angiogenesis or tumor growth and metastasis can be inhibited. | 2011-12-08 |
20110300126 | DISPERSION AND DEBUNDLING OF CARBON NANOTUBES USING GEMINI SURFACTANT COMPOUNDS - The current application relates to a method for solubilizing (dispersing and debundling) of carbon nanotubes using a gemini surfactant, which has head groups and a spacer linking the head groups. The dispersion of nanotubes produced by said method can be used as a delivery system for biologically active agents to an organism. | 2011-12-08 |
20110300127 | DRUG-CONTAINING COMPOSITION - It is an object of the present invention to provide a drug-containing composition capable of stably retaining a water-soluble compound without the loss of drug efficacy of a pharmaceutically active ingredient and thus preventing the compound from diffusing in the body, which is unlikely to cause disassociation at a non-target site and thus achieves disassociation/sustained release/delivery specifically at a target site. The present invention provides a composition which is composed of: (a) at least one a water-soluble compound; and (b) a carrier comprising a polymer having binding affinity with the water-soluble compound. | 2011-12-08 |
20110300128 | USE OF FOXP2 AS A MARKER FOR ABNORMAL LYMPHOCYTES AND AS A TARGET FOR THERAPY OF DISORDERS ASSOCIATED WITH ABNORMAL LYMPHOCYTES - The present invention is directed to a method for detecting abnormal lymphocytes said method comprising detecting an amount or expression of the FOXP2 gene in lymphocytes in a sample, wherein an increased amount or expression of the FOXP2 gene in said lymphocytes indicates the presence of abnormal lymphocytes. Additionally, the invention concerns a method for detecting or assessing a condition associated with the presence of abnormal lymphocytes. The methods of the invention may also be useful for diagnosing myeloma or MGUS or for determining the prognosis for patients with lymphoma, myeloma or MGUS. The severity of bone disease or bone colonisation of tumours may also be able to be predicted. Further, treatment of conditions associated with the presence of abnormal lymphocytes using an agent which inhibits FOXP2 expression and/or FOXP2 activity is provided. An antibody which binds to the N-terminus of FOXP2 has also been developed. | 2011-12-08 |
20110300129 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY - Pharmaceutical compositions of the invention include an antigen or a nucleic acid molecule encoding the antigen; one or both of a PPAR ligand and an RxR ligand; and a pharmaceutically suitable carrier. The pharmaceutical composition can optionally include a mitogen or other additives. Also disclosed are methods of inducing B cell differentiation and promoting an immune response against an antigen. | 2011-12-08 |
20110300130 | IMPAIRED WOUND HEALING COMPOSITIONS AND TREATMENTS - Methods, compounds, compositions, kits and articles of manufacture comprising one or more gap junction modulating agents for treatment of wounds that do not heal at expected rates, including chronic wounds, delayed healing wounds, incompletely healing wounds, and dehiscent wounds in a subject in need thereof. | 2011-12-08 |
20110300131 | DETECTION AND TREATMENT OF PANCREATIC, OVARIAN AND OTHER CANCERS - The application provides methods of diagnosis, prognosis, prophylaxis and treatment of ovarian, pancreatic and other cancers using antibodies that specifically bind to denatured CD70. | 2011-12-08 |
20110300132 | 4-AMINOQUINAZOLINE PRODRUGS - This invention relates to prodrugs of 4-aminoquinazoline compounds, and to pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and HER2. | 2011-12-08 |
20110300133 | CHIMERIC AND HUMANIZED ANTIBODIES TO ALPHA5BETA1 INTEGRIN THAT MODULATE ANGIOGENESIS - The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same. | 2011-12-08 |
20110300134 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF - The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6. | 2011-12-08 |
20110300135 | METHOD AND FORMULATION FOR REDUCING AGGREGATION OF A MACROMOLECULE UNDER PHYSIOLOGICAL CONDITIONS - The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of 5% to 20% polyvinylpyrrolidone (PVP) with a molecular weight range of 2000 to 54,000 daltons. The invention further provides a method to minimize inflammation at the injection site during subcutaneous administration of a macromolecule. In further aspects, the invention provides pharmaceutical formulations for subcutaneous administration of a macromolecule, and methods of treating a CD20 positive cancer or an autoimmune disease, comprising administering a humanized anti-CD20 antibody in a pharmaceutical formulation of the invention. The invention further provides an in vitro dialysis method to evaluate the ability of an excipient to reduce aggregation of an antibody or other macromolecule under physiological conditions. | 2011-12-08 |
20110300136 | THERAPY OF AUTOIMMUNE DISEASE IN A PATIENT WITH AN INADEQUATE RESPONSE TO A TNF-ALPHA INHIBITOR - The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor. | 2011-12-08 |
20110300137 | Use of lumefantrine and related compounds in the treatment of cancer - The present application discloses the use of the anti-malarial drug lumefantrine and related compounds in the treatment of cancer. | 2011-12-08 |
20110300138 | HUMAN ANTI TSHR ANTIBODIES - According to one aspect there is provided an isolated human antibody molecule which binds to the TSHR and which reduces ligand-induced stimulation of the TSHR but has no effect on TSHR constitutive activity, wherein the isolated human antibody molecule has the characteristic of patient serum TSHR autoantibodies of inhibiting TSH and M22 binding to the TSHR. | 2011-12-08 |
20110300139 | GENERATION, EXPRESSION AND CHARACTERIZATION OF THE HUMANIZED K33N MONOCLONAL ANTIBODY - The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth. | 2011-12-08 |
20110300140 | ANTIGEN BINDING POLYPEPTIDES - The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. | 2011-12-08 |
20110300141 | Novel Alphabeta-Binding protein and its peptide derivatives and uses thereof - A protein kinase C inhibitor that binds B-amyloid and its peptide derivatives with the same function are disclosed. These may be useful in the treatment of Alzheimer's disease, for example as pseudo vaccines comprising antibodies, or as part of fusion proteins which are able to pass through cell membranes or through the blood-brain barrier. Methods of using the PKC inhibitor and its peptide derivatives for treating Alzheimer's disease are also disclosed. | 2011-12-08 |
20110300142 | USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS - The invention relates to the use of 1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof. | 2011-12-08 |
20110300143 | PRENATAL ENZYME REPLACEMENT THERAPY - The invention contemplates transplacental enzyme replacement therapy (ERT) for deficiency of a polypeptide such as a tissue-nonspecific alkaline phosphatase (TNSALP) by administering a before-described pharmaceutical composition to a pregnant animal whose fetus or embryo is in need of such therapy. The fusion protein of such a composition comprises a water-soluble TNSALP portion, e.g., C-terminus-truncated TNSALP peptide-bonded to an IgG1 antibody Fc portion. | 2011-12-08 |
20110300144 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER - The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject. | 2011-12-08 |
20110300145 | Interferon Alpha Antibodies And Their Uses - The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention. | 2011-12-08 |
20110300146 | ANTI-CMET ANTAGONISTS | 2011-12-08 |
20110300147 | Inhibiting tumor cell invasion, metastasis and angiogenesis - The present invention relates to new compositions and methods useful for preventing, treating and diagnosing metastatic and/or invasive cancer and undesirable angiogenesis. For example, the invention relates to inhibitors of proteases that are specifically expressed in tumors, prodrugs activated in the tumor microenvironment and methods for using those inhibitors and prodrugs to inhibit angiogenesis and tumor cell invasion. | 2011-12-08 |
20110300148 | IL-4-DERIVED PEPTIDES FOR MODULATION OF THE CHRONIC INFLAMMATORY RESPONSE AND TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to small peptides derived from a cytokine, interleukin-4 (IL-4), capable of binding to the IL-4 receptors and inhibiting macrophage activation, and thereby preventing the onset of inflammatory response. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein IL-4 plays a prominent role. | 2011-12-08 |
20110300149 | LJUNGAN VIRUS - The present invention relates to a new group of Ljungan viruses, proteins expressed by the viruses, antibodies to the viruses and proteins, vaccines against the viruses, diagnostic kits for detecting the viruses, uses of the viruses, proteins, antibodies and vaccines in therapy, uses of the viruses, proteins, antibodies and vaccines in treating diseases caused by the viruses and methods of treatment for treating diseases caused by the viruses. | 2011-12-08 |
20110300150 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE - Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates. | 2011-12-08 |
20110300151 | USES AND COMPOSITIONS FOR TREATMENT OF HIDRADENITIS SUPPURATIVA (HS) - The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treating hidradenitis suppurativa in a subject. | 2011-12-08 |
20110300152 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS - Compositions and methods are provided for modulating cell-cell fusion by using agents that modulate expression, activity, or function of intermediate-conductance calcium-activated potassium (SK4) channel. In some embodiments, the compositions and methods of the invention provide for inhibition of multi-nucleated osteoclastogenesis and cell-cell fusion, especially cell fusion involving macrophages. In such embodiments, the compositions can comprise inhibitory nucleic acids, monoclonal antibodies or small molecule inhibitors of the SK4 channels and find use in preventing and/or treating various diseases or disorders including bone loss, autoimmune and inflammatory diseases or disorders, implant and transplant rejection, and cancer metastasis. In other embodiments, the compositions and methods of the invention provide for activation of cell-cell fusion. Also provided are methods to screen for SK4 channel modulators (inhibitors or activators) that modulate cell-cell fusion, particularly macrophage cell fusion. | 2011-12-08 |
20110300153 | ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF - Disclosed is an antibody produced using an ostrich. Also disclosed is a method for producing the antibody. By using an ostrich, it becomes possible to produce antibodies (particularly antibodies for medical use), which have been hardly produced by using the mammals such as the mouse and the rat, homogeneously in a single body, in large quantities and in a simple manner. The method can overcome a disadvantage of lot-to-lot variation which may occur in the production of polyclonal antibodies using other animals. | 2011-12-08 |
20110300154 | TREATMENT OF AIRWAY HYPERREACTIVITY - The invention provides strategies for treating and preventing airway hyperreactivity and non-allergic asthma comprising antagonizing IL-17 activity and/or production by iNKT cells. Provided herein is a method of diagnosing non-allergic asthma and airway hyperreactivity comprising neutrophils quantification in sputum. | 2011-12-08 |
20110300155 | MODULATING XRN2 - The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN2 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods. | 2011-12-08 |
20110300156 | HUMAN ANTIBODIES AGAINST TISSUE FACTOR - Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies. | 2011-12-08 |
20110300157 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and to matrix metalloproteinase 2 and methods of using such proteins are described. | 2011-12-08 |
20110300158 | ANTI-SERUM ALBUMIN BINDING VARIANTS - The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts. | 2011-12-08 |
20110300159 | Sulfonated Sclerostin, antibodies, epitopes and methods for identification and use therefor - Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds whichh disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders. | 2011-12-08 |
20110300160 | SULFATION OF WNT PATHWAY PROTEINS - Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation. Additionally, a modified Wnt pathway protein lacking a sulfation site that is present in the native Wnt pathway protein is provided. Also provided is methods of treating a subject having a disease exacerbated by Wnt activation. Additionally, a method of treating a subject having a disease exacerbated by Wnt inhibition is provided. | 2011-12-08 |
20110300161 | Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma - The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma. | 2011-12-08 |
20110300162 | DRUG CONJUGATE COMPOSITION - The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed. | 2011-12-08 |
20110300163 | IgE CH3 Peptide Vaccine - The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 2011-12-08 |
20110300164 | IMMUNOSTIMULATORY DNA:RNA OLIGONUCLEOTIDES - Immunostimulatory sequence-specific RNA oligonucleotides corresponding to 3′ terminal sequences of single-stranded minus-sense RNA genomic RNAs are provided. Also provided are compositions and methods relating to an immunostimulatory 4-mer RNA motif provided as 5′-C/U-U-G/U-U-3′. Incorporation of this short RNA motif is sufficient to confer new and altered immunostimulatory properties in new and existing oligonucleotides, including CpG oligodeoxynucleotides. Also provided are methods for use of the immunostimulatory RNA oligonucleotides and DNA:RNA chimeric oligonucleotides of the invention to induce an immune response in vitro and in vivo, as well as to treat allergy, asthma, infection, and cancer in a subject. Single-stranded oligoribonucleotides of the invention are believed to signal through a Toll-like receptor (TLR) chosen from TLR9, TLR8, TLR7, and TLR3. The oligoribonucleotides can also be used in a method to screen for TLR antagonists. | 2011-12-08 |
20110300165 | SUBSTITUTED ISOXAZOLE COMPOUNDS - Disclosed are compounds of Formula (I) | 2011-12-08 |
20110300166 | Vaccine Compositions for Inducing Immune Responses Against Components of Drusen - Disclosed are compositions and methods for treating or preventing the formation of drusen in a patient in need thereof. The compositions include an effective amount of at least one polypeptide present in drusen, or an immunogenic fragment or variant thereof that induces an immune response against the polypeptide, together with a pharmaceutical carrier, excipient, or diluent. The compositions are suitable as vaccines for treating or preventing drusen and diseases associated with drusen. | 2011-12-08 |
20110300167 | CXCR5 RECEPTOR COMPOUNDS - The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor CXCR5. The CXCR5 receptor compounds are derived from the intracellular loops and domains of the CXCR5 receptor. The invention also relates to the use of these CXCR5 receptor compounds and pharmaceutical compositions comprising the CXCR5 receptor compounds in the treatment of diseases and conditions associated with CXCR5 receptor modulation such as autoimmune diseases including lupus, HIV and rheumatoid arthritis, Primary Sjogren's Syndrome, chronic lymphocytic leukemia, Burkitt Lymphoma, colon and breast cancer tumor metastasis, Multiple Sclerosis and compromised immune function. | 2011-12-08 |
20110300168 | COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST INFLUENZA ANTIGENS - This disclosure provides compositions and methods for inducing an immune response against influenza antigens, for example in elderly populations, as well as a sensitive artificial antigen presenting cell (aAPC) stimulation assay that can be used for expansion and analysis of multiple antigen specific T cell populations simultaneously. | 2011-12-08 |
20110300169 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIGEN - The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer. | 2011-12-08 |
20110300170 | HCV VACCINES - Disclosed are methods and compositions for inducing immune responses against Hepatatis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided. | 2011-12-08 |
20110300171 | FACTOR H BINDING PROTEIN IMMUNOGENS - The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pathogenic bacterial strain which expresses multiple facto H binding proteins. | 2011-12-08 |
20110300172 | FUSION PROTEINS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS FOR TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS - A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems. | 2011-12-08 |
20110300173 | Capsule composition for use as immunogen against Campylobacter jejuni - Immunogenic compositions, and method of using the compositions to elicit an immune response against | 2011-12-08 |
20110300174 | CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION - The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): | 2011-12-08 |
20110300175 | COMPOSITION FOR PROMOTING CONTROL OF TOTAL AND LDL CHOLESTEROL, AND/OR WEIGHT LOSS AND/OR THERMOGENESIS - A composition for promoting control of total and LDL cholesterol and/or weight loss and/or thermogenesis in individuals, the composition including green tea extract in a quantity of about 200 mg to about 300 mg; guarana extract in a quantity of about 160 mg to about 260 mg; yerba mate extract in a quantity of about 100 mg to about 300 mg; and conjugated linoleic acid in a quantity of about 700 mg to 3400 mg. Additionally, the green tea extract is standardized in a content of at least 50% epigallocatechin gallate (EGCG), while the conjugated linoleic acid is standardized in a content of at least 50% of trans10, cis 12-CLA (10-12 CLA), and 50% cis9, trans11-CLA (9-11 CLA). | 2011-12-08 |
20110300176 | Microorganisms for therapy - Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proferating proliferating tissues, particularly tumors, to produce selected proteins and other products. Vaccines containing the microorganisms are provided. Combinations of the microorganisms and anti-cancer agents and uses thereof for treating cancer also are provided. | 2011-12-08 |
20110300177 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation. | 2011-12-08 |
20110300178 | HPV TYPES AND VARIANTS ASSOCIATED WITH CERVICAL CANCER AND THE USES THEREOF - The invention relates to identification of novel sequences associated with cervical cancer, probes and kits for the identification of said sequences, and vaccines suitable for vaccination against new cancer causing HPV types. | 2011-12-08 |